Cited 8 times in
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정병하 | - |
dc.contributor.author | 염준섭 | - |
dc.contributor.author | 정수진 | - |
dc.date.accessioned | 2022-09-14T01:42:12Z | - |
dc.date.available | 2022-09-14T01:42:12Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 0022-5347 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190578 | - |
dc.description.abstract | Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318). Materials and methods: Patient-reported outcomes for pain and fatigue were evaluated using the Brief Pain Inventory-Short Form and Brief Fatigue Inventory. Time to deterioration (TTD) was estimated by Kaplan-Meier method; hazard ratios and 95% confidence intervals were calculated using Cox proportional hazards model. General estimating equations for logistic regression estimated treatment-related differences in the likelihood of worsening pain or fatigue. Results: Compliance for completing the Brief Pain Inventory-Short Form and Brief Fatigue Inventory was high (96% to 97%) in the first year. Median followup times were similar between treatments (19 to 22 months). Median pain TTD was longer with apalutamide than placebo for "pain at its least in the last 24 hours" (28.7 vs 21.8 months, respectively; p=0.0146), "pain interfered with mood" (not estimable vs 22.4 months; p=0.0017), "pain interfered with walking ability" (28.7 vs 20.2 months; p=0.0027), "pain interfered with relations" (not estimable vs 23.0 months; p=0.0139) and "pain interfered with sleep" (28.7 vs 20.9 months; p=0.0167). Likelihood for fatigue and worsening fatigue were similar between groups. Conclusions: Patients with metastatic castration-sensitive prostate cancer receiving apalutamide plus ADT vs placebo plus ADT reported consistently favorable TTD of pain. No difference for change in fatigue was observed with apalutamide vs placebo. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | JOURNAL OF UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Androgen Antagonists / administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage* | - |
dc.subject.MESH | Cancer Pain / diagnosis | - |
dc.subject.MESH | Cancer Pain / drug therapy* | - |
dc.subject.MESH | Cancer Pain / etiology | - |
dc.subject.MESH | Cancer Pain / psychology | - |
dc.subject.MESH | Clinical Deterioration | - |
dc.subject.MESH | Fatigue / diagnosis | - |
dc.subject.MESH | Fatigue / drug therapy* | - |
dc.subject.MESH | Fatigue / etiology | - |
dc.subject.MESH | Fatigue / psychology | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pain Measurement / statistics & numerical data | - |
dc.subject.MESH | Patient Reported Outcome Measures | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Prostatic Neoplasms / complications | - |
dc.subject.MESH | Prostatic Neoplasms / drug therapy* | - |
dc.subject.MESH | Prostatic Neoplasms / mortality | - |
dc.subject.MESH | Prostatic Neoplasms / pathology | - |
dc.subject.MESH | Quality of Life* | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Thiohydantoins / administration & dosage | - |
dc.title | Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Neeraj Agarwal | - |
dc.contributor.googleauthor | Kelly McQuarrie | - |
dc.contributor.googleauthor | Anders Bjartell | - |
dc.contributor.googleauthor | Simon Chowdhury | - |
dc.contributor.googleauthor | Andrea J Pereira de Santana Gomes | - |
dc.contributor.googleauthor | Byung Ha Chung | - |
dc.contributor.googleauthor | Mustafa Özgüroğlu | - |
dc.contributor.googleauthor | Álvaro Juárez Soto | - |
dc.contributor.googleauthor | Axel S Merseburger | - |
dc.contributor.googleauthor | Hirotsugu Uemura | - |
dc.contributor.googleauthor | Dingwei Ye | - |
dc.contributor.googleauthor | Robert Given | - |
dc.contributor.googleauthor | Ethan Basch | - |
dc.contributor.googleauthor | Branko Miladinovic | - |
dc.contributor.googleauthor | Angela Lopez-Gitlitz | - |
dc.contributor.googleauthor | Kim N Chi | - |
dc.identifier.doi | 10.1097/JU.0000000000001841 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A02353 | - |
dc.contributor.localId | A03638 | - |
dc.relation.journalcode | J01921 | - |
dc.identifier.eissn | 1527-3792 | - |
dc.identifier.pmid | 34039013 | - |
dc.identifier.url | https://www.auajournals.org/doi/10.1097/JU.0000000000001841 | - |
dc.subject.keyword | apalutamide | - |
dc.subject.keyword | neoplasm metastasis | - |
dc.subject.keyword | prostatic neoplasms | - |
dc.subject.keyword | quality of life | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.affiliatedAuthor | 정병하 | - |
dc.contributor.affiliatedAuthor | 염준섭 | - |
dc.contributor.affiliatedAuthor | 정수진 | - |
dc.citation.volume | 206 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 914 | - |
dc.citation.endPage | 922 | - |
dc.identifier.bibliographicCitation | JOURNAL OF UROLOGY, Vol.206(4) : 914-922, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.